tracken
Madrigal Pharmaceuticals, Inc. Aktie News
Positiv
The Motley Fool
●
6 Tage alt
Madrigal Pharmaceuticals recently earned an impressive approval from the FDA. The biotech still has work to do to reach its peak potential with this medicine.
Neutral
Seeking Alpha
●
20 Tage alt
Madrigal Pharmaceuticals (NASDAQ:MDGL ) Q1 2024 Results Conference Call May 7, 2024 8:00 AM ET Company Participants Tina Ventura - Chief IRO Bill Sibold - CEO Mardi Dier - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler Eli Merle - UBS Liisa Bayko - Evercore Jay Olson - Oppenheimer Ritu Baral - TD Cowen Thomas Smith - Leerink Partners Akash Tewari - Jefferies Jon Wolleben - Citi...
Neutral
GlobeNewsWire
●
20 Tage alt
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today reports first-quarter 2024 financial results and provides corporate updates.
Positiv
Seeking Alpha
●
26 Tage alt
MDGL has launched Rezdiffra, the first drug approved for nonalcoholic steatohepatitis (NASH). Rezdiffra faces competition from potential off-label use of GLP-1RA drugs like semaglutide and tirzepatide, but there is potential for combination therapy too. Shortages of semaglutide and tirzepatide could help Rezdiffra's initial launch.
Neutral
GlobeNewsWire
●
etwa ein Monat alt
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison.
Neutral
GlobeNewsWire
●
etwa ein Monat alt
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 7 new employees, in each case with a grant date of April 15, 2024, as equity inducement awards under the terms of the company's 2023 Inducemen...
Positiv
InvestorPlace
●
etwa ein Monat alt
Many investors have one or more preferred fundamental or technical indicator. These help to cut through the noise surrounding a stock.
Positiv
The Motley Fool
●
etwa 2 Monate alt
Madrigal Pharmaceuticals recently earned a groundbreaking therapy approval. Axsome Therapeutics is getting closer to transforming its lineup of medicines.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
